Page 14 - Loncode Institute News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Loncode institute. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Loncode Institute Today - Breaking & Trending Today

Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Lund, February 9, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents ....

Hans Kolam , Rebekka Schneider , Rebekka Schneiders , Erasmus Universiteit Medisch , Loncode Institute , Erasmus Universiteit Medisch Centrum , Active Biotech , Cell Stem ,

Investegate |Active Biotech Announcements | Active Biotech: Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Investegate announcements from Active Biotech, Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis ....

Hans Kolam , Rebekka Schneider , Rebekka Schneiders , Erasmus Universiteit Medisch , Loncode Institute , Active Biotech , Erasmus Universiteit Medisch Centrum , Cell Stem , Investegate Announcements , Investegate Company Announcements , Active Biotech , Lobenewswire And Globenewswire ,

Active Biotech enters into global patent license agreement

Lund, February 9, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute. ....

Hans Kolam , Rebekka Schneider , Rebekka Schneiders , Erasmus Universiteit Medisch , Loncode Institute , Erasmus Universiteit Medisch Centrum , Active Biotech , Cell Stem , Stockholm Stock Exchange Acti , Active Biotech ,

Active Biotech: Year End Report 2021

FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular ....

Hans Kolam , Erik Vahtola , Loncode Institute , Active Biotech , Chief Medical Officer , Abuse Regulation , Securities Markets , End Report ,

Investegate |Active Biotech Announcements | Active Biotech: Active Biotech: Year End Report 2021

Investegate announcements from Active Biotech, Active Biotech: Year End Report 2021 ....

Hans Kolam , Erik Vahtola , Loncode Institute , Active Biotech , Year End Report , Chief Medical Officer , Abuse Regulation , Securities Markets , Investegate Announcements , Investegate Company Announcements , Active Biotech , Lobenewswire And Globenewswire ,